Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Roger Hajjar
Icahn School of Medicine at Mount Sinai, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sirdus
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Roger J. Hajjar (the Principal Investigator in this study, and the Director of the Wiener Family Cardiovascular Research Laboratories and the Arthur and Janet C. Ross Professor of Medicine at the Mount Sinai School of Medicine) holds equity ownership in NanoCore Therapeautics, SUMOCOR, and Sirdus (privately-held start-up companies focused on the treatment of cardiovascular diseases). Dr. Hajjar is also a listed inventor and co-inventor on multiple unlicensed intellectual properties and pending patent applications involving therapies for hypertension and cardiovascular diseases.
SUMO1 and SERCA2a Function
Heart failure is associated with abnormal calcium cycling which is related to a decrease in expression and a deficiency in the cardiac Sarcoplasmic Reticulum Calcium ATPase pump (SERCA2a). We have found that in heart failure, acetylation of SERCA2a is increased resulting in worsening cardiac function. In this proposal, we will test whether inhibition of SERCA2a hyper-acetylation in the setting of heart failure improves SERCA2a function thereby enhancing cardiac function.
Filed on April 29, 2019.
Tell us what you know about Roger Hajjar's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Roger Hajjar filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Roger Hajjar | Icahn School of Medicine at Mount Sinai | Conflict of Interest | SUMOCOR | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.